MRI technology developer NeuroGrafix has settled its patent litigation with Siemens Healthcare.
The suit against Siemens was dismissed in November pursuant to a confidential settlement agreement and mutual release, and Siemens has obtained a license for itself and its customers, according to NeuroGrafix.
Because there is no license in place for users of MRI equipment from vendors other than Siemens, NeuroGrafix said that it advises and reminds all non-Siemens users of MR neurography, diffusion imaging (diffusion-tensor imaging [DTI], high-angular-resolution diffusion imaging [HARDI], and Q-ball), or diffusion subtraction neurography that they may be infringing U.S. Patent No. 5,560,360 and its foreign equivalents if they are in the U.S., Japan, Europe, Canada, or Australia.
The company said it intends to continue asserting its patent rights against unlicensed infringers. Patent infringement litigation between NeuroGrafix and the Regents of the University of California is ongoing in U.S. Federal District Court, NeuroGrafix said.
